Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
Can AI disrupt the software business model?
stocks
Market is misinterpreting AI impact on cheap ASX share
Unwarranted sell-off with shares down by half in three months.
stocks
AI is a tailwind for beaten down ASX tech share
Latest earnings report outlines cost reduction potential of AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,420.10 | 16.00 | -0.17% |
| CAC 40 | 8,559.07 | 39.86 | 0.47% |
| DAX 40 | 25,175.94 | 189.69 | 0.76% |
| Dow JONES (US) | 49,482.15 | 307.65 | 0.63% |
| FTSE 100 | 10,806.41 | 125.82 | 1.18% |
| HKSE | 26,640.14 | 125.58 | -0.47% |
| NASDAQ | 23,152.08 | 288.39 | 1.26% |
| Nikkei 225 | 58,856.98 | 273.86 | 0.47% |
| NZX 50 Index | 13,623.01 | 97.43 | 0.72% |
| S&P 500 | 6,946.13 | 56.06 | 0.81% |
| S&P/ASX 200 | 9,185.30 | 17.60 | -0.19% |
| SSE Composite Index | 4,131.20 | 16.03 | -0.39% |